Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Intangibles (2020 - 2025)

Cytek Biosciences (CTKB) has disclosed Intangibles for 6 consecutive years, with $17.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Intangibles changed N/A year-over-year to $17.7 million, compared with a TTM value of $17.7 million through Sep 2025, changed N/A, and an annual FY2024 reading of $20.1 million, down 12.81% over the prior year.
  • Intangibles was $17.7 million for Q3 2025 at Cytek Biosciences, down from $18.6 million in the prior quarter.
  • Across five years, Intangibles topped out at $24.7 million in Q1 2023 and bottomed at $4.3 million in Q4 2022.
  • Average Intangibles over 5 years is $16.9 million, with a median of $19.4 million recorded in 2024.
  • The sharpest move saw Intangibles surged 1629.56% in 2021, then decreased 12.81% in 2024.
  • Year by year, Intangibles stood at $4.7 million in 2021, then decreased by 8.61% to $4.3 million in 2022, then skyrocketed by 432.99% to $23.1 million in 2023, then fell by 12.81% to $20.1 million in 2024, then decreased by 12.18% to $17.7 million in 2025.
  • Business Quant data shows Intangibles for CTKB at $17.7 million in Q3 2025, $18.6 million in Q2 2025, and $20.1 million in Q4 2024.